ARTICLE | Emerging Company Profile
Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies
By choosing to be an early development partner instead of a pipeline company, Outpace thinks it can transform cell and gene therapy across the board
May 18, 2021 11:00 PM UTC
Outpace is taking cell and gene control technology originally in-licensed by Lyell out of that company’s toolbox and into a broad partnering model it thinks could transform the field.
Outpace Bio Inc. launched in March with a $30 million series A round led by Artis Ventures and Lyell Immunopharma Inc., with participation by Abstract Ventures, Civilization Ventures, Mubadala Capital, Playground Global, Sahsen Ventures and WRF Capital. ...
BCIQ Company Profiles